Halozyme Therapeutics Inc (FRA:RV7)
€ 45.9 0.41 (0.9%) Market Cap: 5.88 Bil Enterprise Value: 6.68 Bil PE Ratio: 15.94 PB Ratio: 13.52 GF Score: 85/100

Halozyme Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2021 / 08:40PM GMT
Release Date Price: €35.45 (+1.34%)
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Good afternoon, everyone. My name is Jess Fye. I'm a senior biotech analyst at JPMorgan. And we're continuing the 2021 health care conference today with Halozyme. This year is a little different. So I'm sort of going across the hall for the breakout session. (Operator Instructions)

But without further delay, let me turn it over to Halozyme's CEO, Helen Torley.

Helen I. Torley
Halozyme Therapeutics, Inc. - President, CEO & Director

Thank you, Jess, and thank you, everybody, for joining us today. 2020 was a year of remarkable progress and accomplishments at Halozyme. While we'll give our 2020 financial results in February, I'm pleased to report that we expect our revenues to be within the guidance range of $265 million to $275 million, which represents at least 35% growth year-over-year, and we expect our earnings per share to be in the range of $0.90 to $0.95, which was our -- also our updated guidance. Now this great performance was driven by the ongoing progress in our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot